EU Committee Supports Nexpovio for Heavily Treated Myeloma Patients
A combination of Nexpovio (selinexor) and the corticosteroid…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Dosing Begins in Phase 1 Trial of CERC-007
Cerecor has dosed the first patient in a Phase…
Jakafi Plus Steroid Continuing to Treat Multiple Myeloma in Phase 1 Trial
Combining the corticosteroid methylprednisolone and Jakafi (ruxolitinib), an…
$10M Gift to Open Myeloma Research Center at Ohio State
A new research center at Ohio State University (OSU)…
First Patient Dosed With CYAD-211, a Potential CAR T-cell Therapy
The first patient has been dosed in Celyad Oncology’s…
Early Data Show TNB-383B to be Safe, Effective for Heavily Treated Myeloma
Teneobio‘s bispecific antibody TNB-383B was found to be…
